Cargando…

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells

Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart failure and death. It is characterized by the deposition of extracellular ATTR fibrils in the myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate into restored cardiac function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michalon, Aubin, Hagenbuch, Andreas, Huy, Christian, Varela, Evita, Combaluzier, Benoit, Damy, Thibaud, Suhr, Ole B., Saraiva, Maria J., Hock, Christoph, Nitsch, Roger M., Jan Grimm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149704/ https://www.ncbi.nlm.nih.gov/pubmed/34035264 http://dx.doi.org/10.1038/s41467-021-23274-x

Ejemplares similares

Characterization of conformation-specific, human-derived monoclonal antibodies against TTR aggregates with potential for diagnostic and therapeutic use
por: Michalon, Aubin, et al.
Publicado: (2015)

Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition
por: Arvidsson, Sandra, et al.
Publicado: (2015)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023)

Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function
por: Nakano, Tomoya, et al.
Publicado: (2022)

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
por: Adams, David, et al.
Publicado: (2016)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis
por: Pilebro, Björn, et al.
Publicado: (2016)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis
por: Eldhagen, P., et al.
Publicado: (2021)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
por: Yamaguchi, Hiroki, et al.
Publicado: (2022)

Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study
por: Ponti, Lucia, et al.
Publicado: (2023)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
por: Morier, Agnès, et al.
Publicado: (2015)

Copper mediated amyloid-β binding to Transthyretin
por: Ciccone, Lidia, et al.
Publicado: (2018)

Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019)

Narrative review of pharmacotherapy for transthyretin cardiac amyloid
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Mechanisms of Transthyretin Inhibition of IAPP Amyloid Formation
por: Wasana Jayaweera, Sanduni, et al.
Publicado: (2021)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases
por: Damy, Thibaud, et al.
Publicado: (2023)

Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families
por: Suhr, Ole Bernt, et al.
Publicado: (2019)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Transthyretin and Amyloid in the Islets of Langerhans in Type-2 Diabetes
por: Westermark, Gunilla T., et al.
Publicado: (2008)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H., et al.
Publicado: (2018)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Incidence and Predictors of Ventricular Arrhythmias in Transthyretin Amyloid Cardiomyopathy
por: Knoll, Katharina, et al.
Publicado: (2023)

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy
por: Morioka, Mami, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l9ert2smt86amebh45td4b018c